MAPT and frontotemporal dementia: In vivo PET studies in small samples have shown that neuroinflammation anticipates atrophy in clinically established FTD (Cagnin et al., 2004) and precedes both symptoms and the detectability of tau aggregation by PET in MAPT mutation carriers (Miyoshi et al., 2010; Bevan-Jones et al., 2019).